The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly ...

Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.